• TAXIS Publishes on Efflux Pump Inhibitors in MDPI Journal Antibiotics

    May 26th, 2022News Releases

    Efflux pumps in Gram-negative bacteria such as Pseudomonas aeruginosa provide intrinsic antimicrobial resistance by facilitating the extrusion of a wide range of antimicrobials. Approaches for combating efflux-mediated multidrug resistance involve, in part, developing indirect antimicrobial agents capable of inhibiting efflux, thus rescuing the activity of antimicrobials previously rendered inactive by efflux. Herein, TXA09155 is presented as a novel efflux pump inhibitor (EPI) formed by conformationally constraining our previously reported EPI TXA01182. TXA09155 demonstrates strong potentiation in combination with multiple antibiotics with efflux liabilities against wild-type and multidrug-resistant (MDR) P. aeruginosa.

  • cover captures the breadth and depth of modalities represented in the CARB-X portfolio of nontraditional therapeutics and preventatives and spotlights exemplar projects in the areas of protein therapeutics, potentiators, microbiome-modifying agents, bacteriophage products, anti-virulence approaches, and peptide therapeutics.

    TAXIS Pharmaceuticals appears in August special issue on Antibiotic Alternatives in ACS Infectious Diseases

    August 13th, 2021News Releases

    Efflux Pump Inhibitor (EPI) drug candidates appears in the August 13th special Antibiotic Alternatives issue of ACS Infectious Diseases. The paper titled “The CARB-X Portfolio of Nontraditional Antibacterial Products”

  • WHO Names TAXIS’ TXA709 as One of Only 2 (out of 26) Antibacterials Meeting All Innovation Criteria

    April 16th, 2021News Releases

    On April 15, 2021, the World Health Organization (WHO) released their report titled “2020 Antibacterial Agents in Clinical and Preclinical Development” naming TAXIS Pharmaceuticals’ FtsZ inhibitor drug candidate TXA709 as one of only 2 (out of 26) antibacterials targeting WHO priority pathogens that meet all of the WHO innovation criteria (absence of known cross resistance, new class, new target; new mode of action).